Substitute for Form 1449 A & B/PTO				Complete if Known		
				Application Number	10/561,483	
INFOR	MATION	DISCLOS	URE	Confirmation Number	8172	
	MENT BY			Filing Date	December 20, 2005	
				First Named Inventor	Shigenori OHKAWA	
(use as	many sheet	's as neces:	sary)	Art Unit	1609	
				Examiner Name	Havlin, Robert H.	
Sheet	1	of	1	Attorney Docket Number	Q101075	

U.S. PATENT DOCUMENTS						
Examiner Cite Initials* No.1	Cita	Document	Number	Publication Date MM-DD-YYYY		
		Number	Kind Code ¹ (if known)		Name of Patentee or Applicant of Cited Document	
RA		US 6,172,085	BI	01-09-2001	OHKAWA et al.	
1		US 6,479,536	BI	11-12-2002	OHKAWA et al.	
		US 5,376,681	Α	12-27-1994	AONO et al.	
		US 6,525,087	B2	02-25-2003	MITTENDORF et al.	
		US 7,030,139	B2	04-18-2006	CHENG et al.	
7		US 6,930,118	B2	08-16-2005	MOLONEY et al.	
4		US 6,509,352	ВІ	01-21-2003	INABA et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Cite No.1	Foreign Patent Document			Publication Date	Name of Patentee or		
		Country Code ³	Number ⁴	Kind Code ^s (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
M		wo	97/28143	Al	08-07-1997	THE PROCTER & GAMBLE COMPANY	
		EP	1 136 477	Al	09-26-2001	TAKEDA CHEMICAL INDUSTRIES, LTD.	
		wo	96/07651	AI	03-14-1996	THE PROCTER & GAMBLE COMPANY	
1		EP	1 323 716	AI	07-02-2003	TAKEDA CHEMICAL INDUSTRIES, LTD.	
7		WO	96/18391	A2	06-20-1996	LIFEGROUP S.P.A.	
7		WO	96/02248	Al	02-01-1996	ELI LILLY AND COMPANY	
		JP	2000-256323	A	09-19-2000	JAPAN TOBACCO INC.	English Abstract
		wo	02/085866	Al	10-31-2002	ASTRAZENECA AB	
		WO	02/036590	Al	05-10-2002	AMRAD OPERATIONS PTY LTD	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶		
pst		OHKAWA et al., "5-Aminocoumarans: Dual Inhibitors of Lipid Peroxidation and Dopamine Release with Protective Effects against Central Nervous System Trauma and schemia", J. Med. Chem. 1997, 40, pp. 559-573.			
1		JANUSZ et al., "New Cyclooxygenase-2/5-Lipoxygenase Inhibitors. 3. 7-tert-Butyl-2,3-dimethylbenzofuran Derivatives as Gastrointestinal Safe Anttinflammatory and Analgesic Agents: Variations at the 5 Position", J. Med. Chem. 1998, 41, pp. 3515-3529.			

Examinar Signatura	16/14	Date Considered	9/6/07
Examiner Signature		Date Considered	1 1 0 1 0 1

[•]EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranct. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.